Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey,
Ph.D., the company's president and chief executive officer, will present
at the 34th Annual Cowen and Company Health Care Conference
at 10:00 a.m. EST/7:00 a.m. PST on Tuesday, March 4, 2014 in
During the presentation, Dr. Morrissey will review the company's
development plans and priorities for cabozantinib in 2014. He will also
discuss the company's corporate strategy and financial outlook, and
provide a general business update.
The presentation will be webcast and may be accessed via the Event
Calendar pag under Investors & Media at www.exelixis.com.
Exelixis, Inc. is a biotechnology company committed to developing small
molecule therapies for the treatment of cancer. Exelixis is focusing its
proprietary resources and development efforts exclusively on COMETRIQ®
(cabozantinib). Exelixis has also established a portfolio of other novel
compounds that it believes have the potential to address serious unmet
medical needs, many of which are being advanced by partners as part of
collaborations. For more information, please visit the company's web
site at www.exelixis.com.
Exelixis, the Exelixis logo, and COMETRIQ are registered U.S. trademarks.
[ Back To NFVZone's Homepage ]